Methods for producing parvovirus

JP7588466B2Active Publication Date: 2024-11-22ASAHI KASEI MEDICAL CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2020008613
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-01-22
Publication Date
2024-11-22
Estimated Expiration
2040-01-22

AI Technical Summary

Benefits of technology

【0016】 本発明により、単分散化されたパルボウイルスを製造することが可能となる。これにより、パルボウイルスを用いたウイルス除去膜のウイルスクリアランス試験において、ウイルス除去膜のウイルス分離性能を過大評価することなく、従来よりも正確に評価することが可能となる。ウイルス除去膜のウイルスクリアランスを正確に評価できることは、生物製剤の安全性担保をより正しく行うことができる点で有利である。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588466000001
    Figure 0007588466000001
  • Figure 0007588466000002
    Figure 0007588466000002
  • Figure 0007588466000003
    Figure 0007588466000003
Patent Text Reader

Abstract

To provide a method for producing monodispersed parvovirus.SOLUTION: The present disclosure provides a method for producing monodispersed parvovirus, including the steps 1) of subjecting parvovirus-containing liquid to density gradient ultracentrifugation with organic density gradient liquid and 2) of recovering a fraction containing parvovirus.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing a monodispersed parvovirus. [Background technology]

[0002] Viruses infect and amplify many animals, plants, and microorganisms, including humans. Some viruses have DNA as their genome, while others have RNA, and each has a different mechanism for amplifying. Viruses cannot multiply on their own, but can infect the cells of animals, plants, or microorganisms and use the functions of those cells to replicate themselves.

[0003] One of the main viruses is the parvovirus. All viruses in the Parvoviridae family have single-stranded DNA of 4 to 6 kb, and the diameter of the virus particle is 18 to 22 nm, the virus particle is icosahedral, does not have an envelope, and is resistant to ether, chloroform, heat, etc. (Non-Patent Document 1).

[0004] Viruses in the Parvoviridae family are divided into the Parvovirinae and Densovirinae subfamilies. Viruses in the Parvovirinae subfamily are classified into several genera. The genus Dependovirus includes the adeno-associated virus used in gene therapy, the genus Erythrovirus includes B19, which infects humans and causes fifth disease, and the genus Parvovirus includes canine parvovirus (CPV), feline parvovirus (FPV), goose parvovirus (GPV), and minute virus of mice (MVM).

[0005] Parvovirus is a virus that is considered important in the pharmaceutical industry. Biologically derived pharmaceuticals such as genetically modified preparations (biopharmaceuticals) and antibody drugs need to evaluate and validate the virus clearance (removal performance) of the manufacturing process to ensure that the preparation is not contaminated by viruses (virus safety). Research literature on the virus safety of biopharmaceuticals also lists minute virus of mice (MVM) as a virus that may be contaminated in cell and tissue processed products (Non-Patent Document 2).

[0006] Therefore, the virus clearance of each process is measured by adding MVM to the intermediate product before each process of pharmaceutical manufacturing and quantifying the virus amount before and after the process. 7 Units or 10 8 In some cases, it may be necessary to prepare more than 10 units of virus. Furthermore, in practice, the same conditions must be repeated multiple times for one test, so 7 Units or 10 8 It is necessary to prepare many times the amount of virus per unit. Thus, a large amount of virus solution is required to perform a viral clearance test for a biopharmaceutical.

[0007] Known methods for producing parvovirus include culturing host cells, infecting and culturing the virus, and purifying the collected virus. Known host cells for minute virus of mice include A9 cells and 324K cells (human fibroblasts transformed with simian virus 40, sometimes written as NB324K) (Patent Documents 1 to 3, Non-Patent Document 3). 8 TCID 50 Methods for producing minute virus of mice with a high infectivity titer of 1000 μg / mL or more are also known (Patent Documents 2 and 4).

[0008] If the recovered virus has a sufficiently high titer, it can be used in a virus clearance test by only low-speed centrifugation or membrane filtration for separation of microorganisms without the need for purification such as concentration (Patent Document 2, Patent Document 4). In addition, a method of increasing the virus infectivity titer or decreasing the impurity concentration by performing concentration and purification is also known (Patent Document 1). [Prior art documents] [Patent documents]

[0009] [Patent Document 1] US Patent Application Publication No. 2012 / 0088228 [Patent Document 2] International Publication No. 2017 / 077804A1 [Patent Document 3] International Publication No. 2011 / 130119A2 [Patent Document 4] International Publication No. 2014 / 080676A1 [Non-patent literature]

[0010] [Non-Patent Document 1] TW Tinsley and JF Longworth. (1973) J. gen. Virol.(20), 71-5. pp.7-15.”Parvovirus” [Non-Patent Document 2] T. Kobayashi et.al. (2013) Bull. Natl. Inst. Health Sci. 131. pp.7-15. [Non-Patent Document 3] Susanne I. Lang et. al. (2005) J. Virol,Vol.79.,No.1. pp. 289-298 [Non-Patent Document 4] Virus Experiments, Maruzen Publishing, National Institute of Health Alumni Association, pp22-23 [Non-Patent Document 5] MSCollett et. al. (1983) J. Virol. pp.842-854. [Non-Patent Document 6] BW. Kong et.al. (2008) Bio Techniques. 44: 97-99 Summary of the Invention [Problem to be solved by the invention]

[0011] An object of the present invention is to provide a method for producing a parvovirus that enables accurate evaluation of the virus clearance performance of a virus removal membrane, etc. Another object of the present invention is to provide a method for monodispersing an aggregated parvovirus. [Means for solving the problem]

[0012] When a membrane separation process having a separation mechanism based on the sieving effect of particle size (size exclusion) is introduced as a virus removal process in the manufacture of biological products, the parvovirus clearance ability of the virus removal membrane is evaluated. The present inventors have found that some viruses exist in an associated state, and when such associated viruses are used in a virus clearance test, viruses that would normally pass through the virus removal membrane are captured by the virus removal membrane, and there is a risk of overestimating (overestimating) the virus removal performance. This is because when viruses exist in an associated state, the actual size of the virus becomes larger than the size of a single molecule.

[0013] The present inventors first discovered the above problem, and as a result of their intensive research, they discovered that it is possible to obtain monodispersed viruses by subjecting the viruses to density gradient ultracentrifugation using an organic density gradient liquid. They also discovered that by using the monodispersed viruses in a virus removal membrane virus clearance performance evaluation test, it is possible to evaluate the virus removal membrane virus clearance performance more accurately than before, which led to the completion of the present invention.

[0014] Conventionally known methods for producing and purifying parvovirus aim to increase the infectivity of parvovirus or to reduce the impurity concentration, and do not pay any attention to the dispersion state of virus particles, and no method for obtaining a virus in a monodispersed state is known. In addition, there are cases where the virus dispersibility has actually been verified by filtering a parvovirus suspension through a 0.1 μm membrane to confirm whether it passes through (Patent Document 1). However, the size of one parvovirus molecule is 18 to 22 nm (Non-Patent Document 1), and even an aggregate of 36 to 44 nm in size in which two molecules are associated, or an aggregate in which three or four molecules are associated, passes through a 0.1 μm membrane. Therefore, verification using filtration through a 0.1 μm membrane is insufficient to confirm the aggregation state of parvovirus, and it cannot be said that the aggregation state has been confirmed. When a virus suspension filtered through a 0.1 μm membrane is used in a virus clearance test, the possibility of containing these aggregates cannot be denied, and there is a risk of overestimation in the evaluation of a size separation membrane.

[0015] That is, the present invention includes the following. [1] A method for producing a monodispersed parvovirus, comprising: 1) the steps of subjecting a parvovirus-containing solution to density gradient ultracentrifugation using an organic density gradient solution; and 2) the steps of recovering a fraction containing the parvovirus. [2-1] The method according to [1] above, wherein the parvovirus-containing liquid is a culture medium of parvovirus. [2-2] The method according to [2-1] above, wherein the parvovirus culture medium is a culture supernatant and / or an infected cell lysate obtained by culturing cells infected with the parvovirus. [3] The method according to any of [1] to [2-2] above, wherein the logarithmic removal rate (LRV) when the monodispersed parvovirus is filtered through a membrane having a pore size of 35 nm is less than 1.0. In addition, when a citation is indicated as a range such as [1] to [2-2] above, and an item with a subnumber such as [2-1] is located within that range, it means that the item with the subnumber such as [2-1] is also cited. The same applies below. [4] The method according to any one of [1] to [3] above, wherein the density gradient in the density gradient ultracentrifugation is a step gradient density gradient. [5] The method according to any one of [1] to [4] above, wherein the density gradient solution contains sucrose. [6] The method according to [5], wherein the organic medium-containing liquid is a stepwise density gradient liquid containing at least a sucrose solution layer of 40% or less and a sucrose solution layer of more than 40%. [7] The method according to any one of [4] to [6] above, wherein the organic medium-containing liquid is a stepwise density gradient liquid containing a 40% sucrose solution layer and a 60% sucrose solution layer. [8] The method according to any one of [4] to [6] above, wherein the organic medium-containing liquid is a stepwise density gradient liquid including a 15% sucrose solution layer, a 30% sucrose solution layer, a 45% sucrose solution layer, and a 60% sucrose solution layer. [9] The method according to any one of [1] to [3] above, wherein the density gradient is a continuous density gradient. [10-1] The method according to [9] above, wherein the density gradient solution is a continuous density gradient solution prepared by allowing a solution layered in a stepwise manner (step gradient) to stand for 12 to 24 hours. [10-2] The method according to [9] above, wherein the density gradient solution is a continuous density gradient solution prepared by allowing a solution layered in a stepwise manner (step gradient) to stand for 14 to 18 hours.

[11] The method according to any one of [9] to [10-2] above, wherein the stepwise layered solution is a solution containing at least a sucrose solution layer of 40% or less and a sucrose solution layer of more than 40%.

[12] The method according to any one of [9] to

[11] above, wherein the stepwise layered solutions include a 15% sucrose solution layer, a 30% sucrose solution layer, a 45% sucrose solution layer, and a 60% sucrose solution layer. [13-1] The method according to any one of [1] to

[12] above, wherein the product (h×g) of the relative centrifugal force (g) x centrifugation time (h) of the density gradient ultracentrifugation is 20,000 to 300,000 (h×g). [13-2] The method according to any one of [1] to

[11] , wherein the product (h×g) of the relative centrifugal force (g) x the centrifugation time (h) of the density gradient ultracentrifugation is 1974100 (h×g). [13-3] The method according to any one of [1] to

[11] , wherein the relative centrifugal force (g) × centrifugation time (h) of the density gradient ultracentrifugation is 103,900 (g) × 19 (h).

[14] The method according to any of [1] to [13-3] above, further comprising a step of exchanging the solvent of the fraction containing the parvovirus.

[15] The method according to any one of [1] to

[14] above, wherein the recovery rate of the parvovirus is 50% or more.

[16] The method according to any one of [1] to

[15] above, wherein the parvovirus is minute virus of mice. [17-1] A method for evaluating the virus clearance performance of a virus removal membrane, comprising a step of adding a monodispersed parvovirus to a protein-containing solution. [17-2] A method for evaluating the virus clearance performance of a virus removal membrane, comprising a step of adding a parvovirus monodispersed by the method according to any one of the methods [1] to

[16] to a protein-containing solution.

[18] A step of subjecting the parvovirus-containing liquid to density gradient ultracentrifugation using an organic density gradient liquid to obtain a monodispersed parvovirus; and adding the monodispersed parvovirus-containing solution to a protein-containing solution. A method for evaluating the virus clearance performance of a virus removal membrane, comprising:

[19] The method according to

[17] or

[18] , further comprising a step of subjecting a protein-containing solution to which the monodispersed parvovirus-containing solution has been added, to a virus removal membrane.

[20] The method according to any one of [17-1] to

[19] above, further comprising a step of evaluating viral removal or inactivation.

[21] The method according to any one of [17-1] to

[20] above, having the characteristics described in [1] to

[15] above. Effect of the Invention

[0016] According to the present invention, it is possible to produce a monodispersed parvovirus. As a result, in a virus clearance test of a virus removal membrane using the parvovirus, it is possible to evaluate the virus separation performance of the virus removal membrane more accurately than before without overestimating it. Being able to accurately evaluate the virus clearance of a virus removal membrane is advantageous in that the safety of a biological product can be more accurately ensured. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] The following describes the form for carrying out the present invention (hereinafter, sometimes referred to as "embodiment"). The present invention is not limited to the following embodiment, and can be practiced in various modifications within the scope of the gist. Furthermore, the following embodiment is merely an example of a method for embodying the technical idea of ​​the present invention, and the present invention is not limited to these examples.

[0018] In one embodiment, the parvovirus is exemplified by adeno-associated virus, human parvovirus B19, canine parvovirus (CPV), feline parvovirus (FPV), goose parvovirus (GPV), or minute virus of mice (MVM). A preferred example of the parvovirus is minute virus of mice. Minute virus of mice is a virus belonging to the Parvovirus genus in the Parvoviridae family, the Parvovirinae subfamily therein. Minute virus of mice is also called MVM (Minute virus of mice) or MMV (Mice minute virus).

[0019] In one embodiment, the parvovirus to be monodispersed may be in an associated state. A parvovirus culture solution obtained by culturing host cells infected with a parvovirus in a medium is also an example of the parvovirus-containing solution. The parvovirus may be present in a state of infecting host cells, or may be present in a free state in the parvovirus-containing solution (e.g., a parvovirus culture solution). The parvovirus-containing solution may be a culture supernatant of a culture obtained by infecting host cells with a parvovirus and culturing the cells, and / or a lysate of the infected cells (hereinafter, also simply referred to as "infected cell lysate"). An example of the "culture supernatant" is a medium after infection and culture. An example of the "infected cell lysate" is a so-called lysate obtained by disrupting cells after infection and culture by freezing and thawing or homogenization.

[0020] Freezing and thawing or homogenization can be performed on the cells and culture supernatant together, or after separating the culture supernatant, an appropriate liquid (fresh medium, buffer such as PBS, etc.) can be added to the cells. Cell destruction by freezing and thawing is a well-known method (Non-Patent Document 4, Non-Patent Document 6). Freezing and thawing can be repeated alternately 3 to 6 times. Usually, five freeze-thaw cycles are sufficient to destroy the cells and recover the viruses inside them. Cell homogenization is also a commonly used method, and if the cells are destroyed by a known method (Non-Patent Document 4, etc.), the viruses inside the cells can be recovered. Alternatively, the viruses inside the cells can be extracted by destroying the cells by osmotic pressure caused by adding pure water (Non-Patent Document 6).

[0021] From the viewpoint of reducing the amount of impurities contained in the parvovirus-containing liquid and increasing purification efficiency, it is preferable to purify from a culture supernatant containing few impurities. Furthermore, in order to further reduce the amount of impurities, it is preferable that the medium is a serum-free medium that does not contain serum.

[0022] In one embodiment, the culture medium is not particularly limited as long as it is capable of culturing host cells infected with a parvovirus, and examples of the culture medium include a liquid containing Dulbecco's Modified Eagle's Medium, Eagle's Minimal Essential Medium, or F-12 medium.

[0023] In one embodiment, the parvovirus-containing liquid is not particularly limited as long as it contains a parvovirus, and examples of the liquid include a solution, a suspension, and a gel-like liquid, with a solution being a preferred embodiment. An example of the solution is a culture solution of the parvovirus.

[0024] In one embodiment, the pH of the parvovirus-containing liquid is not particularly limited as long as the parvovirus can be cultured, and examples of the lower limit of the pH include 5 or more, 6 or more, and 7 or more. Examples of the upper limit of the pH include 10 or less, 9 or less, and 8 or less.

[0025] In one embodiment, the serum content of the parvovirus-containing liquid is, for example, 0%, 3%, 5%, or 10%.

[0026] In one embodiment, examples of serum contained in the parvovirus-containing liquid include FBS (fetal bovine serum) and FCS (calf serum).

[0027] In one embodiment, the virus concentration in the parvovirus-containing solution is not particularly limited as long as it is a virus concentration at which monodispersed viruses can be obtained by density gradient ultracentrifugation. 12 Units / mL or less, 10 11 Units / mL or less, 10 10 Units / mL or less, or 10 9 Examples include units / mL or less. The lower limit is 10 6 Units / mL or more, 10 7 Units / mL or more, or 10 8 Examples include units / mL or more.

[0028] In one embodiment, the solute of the organic density gradient solution used in the density gradient ultracentrifugation is not particularly limited as long as it is an organic density gradient solution from which a monodispersed parvovirus can be obtained by density gradient ultracentrifugation, and examples of the solute include sucrose (cancer sugar) and iodixanol, with sucrose (cancer sugar) being a preferred embodiment.

[0029] In one embodiment, the solvent for the organic density gradient solution is not particularly limited as long as it is a liquid capable of dissolving the solutes of the organic density gradient solution, but examples thereof include TNE buffer (Tris-NaCl-EDTA buffer), TE buffer (Tris-EDTA buffer), and PBS buffer (Phosphate buffered saline), and TNE buffer is preferred.

[0030] In one embodiment, the pH of the organic density gradient solution is not particularly limited as long as it is a pH that can limit viruses monodispersed by density gradient ultracentrifugation, and examples of the lower limit of the pH include 5.0 or more, 5.5 or more, 6.0 or more, 6.5 or more, and 7.0 or more. Examples of the upper limit of the pH include 9.0 or less, 8.5 or less, 8.0 or less, and 7.5 or less.

[0031] In one embodiment, the monodispersed state (also simply referred to as "monodispersion") refers to a state in which viruses are not associated (aggregated). Specifically, the monodispersion in this embodiment is exemplified by a logarithmic reduction value (LRV) of less than 1.0 when the viruses are filtered through a membrane with a pore size of 35 nm. The association state is exemplified by a state in which parvoviruses are bound to each other and the LRV of the virus is 1.0 or more when the virus is filtered through a membrane with a pore size of 35 nm. The association state is sometimes called an aggregation state. The size of the monodispersed virus is the virus size that is usually recognized as the virus. Therefore, the monodispersion of the virus can prevent the virus clearance of the virus removal membrane from being overestimated as a result of the virus size increasing due to virus association.

[0032] The LRV can be calculated as follows: LRV = {viral infectivity before filtration (log 10 [TCID 50 / mL])}-{Virus infectivity after filtration (log 10 [TCID 50 / mL)

[0033] The infectivity titer is a unit that expresses the amount (concentration) of a virus. There are two methods for measuring the infectivity titer: the end point method, which determines the minimum infectious unit, and the method of calculating local lesions formed by the virus. In the end point method, the virus is serially diluted, inoculated into a certain number of cultured cells, cultured for a certain period of time, and the infection is judged to be positive or negative, to determine the dilution ratio at which 50% infection is positive, called the 50% infection end point (TCID 50 The most common method for calculating local lesions is the plaque method, in which the virus is inoculated onto a monolayer culture of host cells, the virus is allowed to adhere to the surface, and then a medium containing agar is overlaid to solidify, and the number of plaques formed is counted according to the number of viruses inoculated. When the plaque method is used, the unit of infectious titer in the LRV calculation formula mentioned above is log 10 [TCID50 / mL] instead of log 10 The ratio is expressed as [pfu / mL]. pfu is an abbreviation for plaque forming unit.

[0034] In one embodiment, the parvovirus-containing liquid is not particularly limited as long as it is a liquid in which the parvovirus can exist in a monodispersed state, and examples of the liquid include a solution, a suspension, and a gel-like liquid, and examples of the liquid include a PBS buffer solution, a TNE buffer solution, and a TE buffer solution.

[0035] In one embodiment, the pH of the parvovirus-containing liquid is not particularly limited as long as the parvovirus can exist in a monodispersed state, and examples of the lower limit of the pH include 5 or more, 6 or more, and 7 or more. Examples of the upper limit of the pH include 10 or less, 9 or less, and 8 or less.

[0036] In one embodiment, the composition of the parvovirus-containing solution is, for example, a PBS buffer solution having a pH in the range of 7 to 8, containing an organic density gradient solution.

[0037] In one embodiment, the parvovirus can be produced, for example, as follows. First, a (non-infected) host cell of the parvovirus is cultured. The host cell is not particularly limited as long as it is a cell that can be infected and amplified by the parvovirus, and mouse fibroblast A9, simian virus 40-transformed human fibroblast (324K cell, NB324K cell, etc.), Chinese hamster ovary cell (CHO), etc. can be used.

[0038] In one embodiment, examples of the method for culturing the host cells include a method using a culture flask, a method in which the cells are immobilized on a microcarrier and cultured with stirring, a method using a roller bottle, or a method using a bioreactor.

[0039] In one embodiment, the culture flask may be a commercially available tissue culture flask, such as a Falcon tissue culture flask, or a multi-well plate.

[0040] In one embodiment, the microcarrier is commercially available, for example, Cytodex or Cytopore, manufactured by GE Healthcare.

[0041] In one embodiment, the roller bottle is a commercially available example of such a bottle, such as a CELLMASTER cell culture roller bottle manufactured by Greiner Bio-One.

[0042] In any of the culture methods, the culture temperature is, for example, 33° C. to 39° C., which is generally applied to mammalian cell culture, and is particularly preferably 37° C. The pH of the medium is preferably 7 to 8, which is generally applied to mammalian cell culture. The concentration of the medium is preferably a concentration that is isotonic (has the same osmotic pressure) as that of the host cells.

[0043] In one embodiment, examples of the medium include DMEM medium, MEM medium, CD medium, SFM medium, OptiPro SMF medium, Viral Vaccine Platform medium (SFM4Mega Vir medium, Vaccine Xpress medium, CDM4Avian medium), etc. These media are available from Gibco, Thermo Fisher, GE Healthcare, etc.

[0044] In order to reduce the amount of impurities other than parvovirus in the parvovirus-containing solution, it is desirable that the medium is a serum-free medium that does not contain serum. Efficient amplification of the virus can be achieved by culturing in a medium containing serum such as fetal bovine serum (FBS). In addition, by exchanging the culture medium from a serum-containing medium to a serum-free medium 24 hours or more before recovery, the virus can be produced in a medium that does not contain impurities derived from serum and recovered, for example, by using the method described in Patent Document 2. In order to remove large particulate impurities such as cell debris present in the parvovirus-containing solution before the density gradient ultracentrifugation in the next step, low-speed centrifugation and sterilization membrane filtration can also be performed. The low-speed centrifugation can be performed by selecting a gravitational acceleration at which the virus does not precipitate but the cell debris precipitates. For example, centrifugation at 3,000 rpm x 20 minutes or centrifugation at 12,000 g x 30 minutes (Non-Patent Document 5) is performed, but the conditions are not limited to these. In addition, a membrane with a pore size of 0.45 μm, 0.22 μm, or 0.1 μm can be used for sterilization membrane filtration. Examples of membranes having these pore sizes include Thermo Fisher bottle top filters (0.45 μm), Thermo Fisher bottle top filters (0.22 μm), Merck Millex filters (0.22 μm, 0.45 μm), Merck Sterivex filters (0.22 μm, 0.45 μm), and Sartorius Minisart filters (0.2 μm).

[0045] Next, the cultured uninfected host cells are infected with a parvovirus seed. The seed virus can be a virus purchased from ATCC or the like, multiplied by the method described in the present specification, aliquoted into cryotubes, or the like, and frozen and stored at -80°C. Examples of purchased seed viruses include VR-742 (ATCC) if the virus is PPV, and VR-1346 (ATCC) if the virus is MVM.

[0046] Next, the culture supernatant is collected. The culture time until the culture supernatant is collected is set to allow the virus to amplify sufficiently. The amount of virus in the culture supernatant and in the cells is measured every day, and the most preferable time can be set. To measure the amount of virus in the cells, after removing the culture supernatant, the cells are disrupted by freezing and thawing 3 to 5 times, and the infectivity titer can be measured. The culture time from virus infection to collection is, for example, 5 to 14 days.

[0047] The culture supernatant cultured for a time sufficient for the parvovirus to amplify sufficiently contains the parvovirus. However, when the parvovirus is not released into the culture supernatant and remains inside the infected host cells, the infected host cells in the culture vessel can be frozen and thawed 3 to 5 times to disrupt the cells and recover the virus that has come out of the cells. Freezing and thawing can be performed with the culture medium still in the culture vessel, or can be performed after replacing the medium with a buffer such as PBS (phosphate buffered saline) or TNE (Tris buffer + NaCl + EDTA). A parvovirus-containing solution can be obtained by the above method.

[0048] Next, the obtained parvovirus-containing liquid is applied to density gradient ultracentrifugation. Density gradient ultracentrifugation is one of the methods of ultracentrifugation that are widely used. Ultracentrifugation is a method of centrifuging at a gravity greater than that of a normal centrifuge, which can precipitate even fine particles such as viruses that do not precipitate by normal centrifugation. At this time, if the liquid density in the centrifuge tube is higher than that of the virus, the virus does not settle to the bottom and stops settling above the liquid. If a liquid with a higher density than the virus and a liquid with a lower density are layered in the centrifuge tube, the virus passes through the lower density liquid and settles, but cannot settle in the liquid with a higher density than the virus. In this way, by performing ultracentrifugation under a density gradient, the contained substances come to remain at different positions depending on their density. This method is called density gradient ultracentrifugation.

[0049] The force applied in ultracentrifugation is expressed as a number of times the force of the Earth's gravity (g). This force is expressed as RCF (relative centrifugal force), which is an abbreviation for Relative Centrifugal force.

[0050] In one embodiment, density gradient ultracentrifugation can be performed, for example, as follows. First, organic density gradient solutions with different concentrations are prepared. They are layered in an ultracentrifuge tube so that the lighter solution is layered on the higher density solution. At this time, the lighter solution may be added first and the heavier solution may be injected below it with a syringe or pipette, or the heavier solution may be added first and the lighter solution may be placed on top. Next, the parvovirus-containing solution is layered on top of the layered organic density gradient solutions. Then, the solution is subjected to an ultracentrifuge. By ultracentrifugation, the components in the parvovirus-containing solution layered last are separated into layers in the organic density gradient solution according to their densities. The tube is removed from the ultracentrifuge, and the solution is fractionated from the upper layer to the lower layer of the tube. The fractionation can be performed by sucking up a fixed amount from the top with a pipette, by inserting a needle of a syringe into the side of the tube and sucking up only a specified portion, or by making a hole in the bottom of the tube with a needle and fractionating a fixed amount in sequence from the bottom layer.

[0051] In one embodiment, the parvovirus-containing solution can be appropriately concentrated depending on the size of the rotor used. As a concentration method, a known method such as salting out precipitation using CsCl2, polyethylene glycol (PEG) precipitation, filtration through an ultrafiltration membrane, or precipitation by ultracentrifugation can be used. Precipitation by ultracentrifugation is exemplified as a preferred method from the viewpoint of freely setting the concentration rate or facilitating solvent exchange.

[0052] For example, when concentrating a parvovirus by ultracentrifugation, the product (h×g) of the relative centrifugal force (g) and the centrifugation time (h) can be, for example, up to 1,200,000 (h×g), up to 700,000 (h×g), or up to 300,000 (h×g), and the lower limit can be, for example, 20,000 (h×g), 10,0000 (h×g), or 200,000 (h×g).

[0053] An example of ultracentrifugation conditions is a method in which ultracentrifugation is performed at 29,400 rpm for 2 hours using an ultracentrifuge (Optima L-90K manufactured by Beckman Coulter) with a Type 45 Ti rotor (manufactured by Beckman Coulter).

[0054] The precipitated parvovirus can then be resuspended in a suitable solvent to obtain a concentrated parvovirus-containing solution.

[0055] The solvent for resuspension may be a commonly used Tris buffer such as TNE buffer, PBS buffer, cell culture medium such as DMEM medium (serum-free), etc. Preferably, TNE buffer, PBS buffer, cell culture medium, more preferably TNE buffer, PBS buffer, DMEM medium (serum-free), and most preferably TNE buffer. The state of the parvovirus when resuspended may be in a dispersed state or an aggregated state.

[0056] Examples of solutes in the organic density gradient solution in density gradient ultracentrifugation include sucrose (cane sugar) and iodixanol. A preferred example of the solute is sucrose.

[0057] When sucrose is used as a solute, sucrose solutions of different concentrations are layered on a centrifuge tube for density gradient ultracentrifugation. The solvent for the sucrose solution can be TE buffer (Tris buffer - EDTA) or the like.

[0058] When parvovirus is subjected to ultracentrifugation, it passes through the 40% sucrose layer. When a 50% sucrose solution and a 40% sucrose solution are layered, and then a parvovirus suspension (concentrated solution) is layered on top of that and ultracentrifuged, the parvovirus can be recovered from the interface between the 40% sucrose layer and the 50% sucrose layer.

[0059] Even when a 60% sucrose layer and a 40% sucrose layer were layered, parvovirus could be recovered from the interface between the two layers after ultracentrifugation.

[0060] The overlay concentration is not limited to these; when 60%, 45%, 30%, or 15% sucrose solutions are overlaid and then a parvovirus suspension (concentrated solution) is overlaid on top of the sucrose solutions and density gradient ultracentrifugation is performed, the parvovirus can be recovered from the 45% layer.

[0061] When 60%, 50%, 40%, and 30% sucrose solutions are layered and then a parvovirus suspension (concentrated solution) is layered on top of that and density gradient ultracentrifugation is performed, the parvovirus can be recovered from the interface between the 50% and 40% layers.

[0062] The relative centrifugal force (g)×centrifugation time (h) of these density gradient ultracentrifugations should be sufficient for the parvovirus to fall to the position of the solution where it is in equilibrium with its own specific gravity, and the product (h×g) of the relative centrifugal force (g) and the centrifugation time (h) should be 1,500,000 (h×g) or more. More preferably, it is 1,800,000 (h×g) or more and 7,000,000 (h×g) or less, and most preferably 1,974,100 (h×g). As an example, when ultracentrifugation is performed at 24,000 rpm using a swing rotor SW-28 of Optima L-90K+ manufactured by Beckman Coulter, the relative centrifugal force is 103,900 g, and the minute virus of mice can be recovered from the target position by performing ultracentrifugation for 19 hours.

[0063] The density gradient solution can be layered either by dispensing a heavy layer and then placing a lighter layer on top, or by dispensing a lighter layer first and then injecting a heavier layer underneath. The industry standard for these ultracentrifugations is to perform them at 4°C to prevent inactivation of the virus.

[0064] In addition, immediately after layering the sucrose solution, the virus suspension can be layered on top and applied to density gradient ultracentrifugation, but if the sucrose solution is left to stand for 8 to 24 hours after layering, the interfaces of the sucrose layers will blend together through diffusion, creating a continuous concentration gradient. Even with this method, the position from which the virus can be recovered after density gradient ultracentrifugation will be the same.

[0065] If the mixture is not allowed to stand after layering, the density gradient will be stepwise, and this is called "step gradient density ultracentrifugation." However, if the mixture is allowed to stand, this becomes "continuous density gradient ultracentrifugation."

[0066] Continuous density gradient ultracentrifugation allows for more precise and precise separation of the substance to be recovered (parvovirus) from the impurities to be removed than step density gradient ultracentrifugation. Different types of ultracentrifugation can be used depending on the purpose.

[0067] The incubation after layering is preferably performed at 1°C to 30°C, more preferably 2°C to 10°C, and most preferably 4°C. If the incubation time is too short, the concentration will not be continuous, and if it is too long, the concentrations will mix too much due to diffusion and the gradient will not be maintained. The incubation time is preferably 12 to 24 hours, more preferably 14 to 18 hours, and most preferably 16 hours.

[0068] The position from which the parvovirus can be recovered after density gradient ultracentrifugation can be determined by collecting appropriate volumes (e.g., 1 mL) of the solution in the centrifuge tube from the top to the bottom after density gradient ultracentrifugation and assaying the infectivity.

[0069] The above density gradient ultracentrifugation may be repeated two or more times to increase the degree of purification. In this case, the solvent concentrations at which the parvovirus can be recovered are equal in the first and second times. The concentration composition of the layers may be changed in the first and second times. For example, in the first time, sucrose concentrations of 60%, 50%, 40%, and 30% are layered, and the interface fraction between 50% and 40% is recovered, and in the second time, density gradient ultracentrifugation is performed with two layers of 60% and 40%, and the interface between both layers is recovered. Alternatively, the reverse may be done.

[0070] In sucrose density gradient ultracentrifugation, the position (sucrose concentration) at which parvovirus is recovered is always constant (between 40% and 50%); therefore, the layering method can be changed depending on the purpose and workability.

[0071] If you want to further reduce the impurity concentration, you can collect the virus at the interface between 40% and 50%. If you do not need to worry about the impurity concentration because it is already sufficiently low, you can collect the virus at an interface with a larger concentration difference, such as between 40% and 60%.

[0072] When the solute of the organic density gradient solution is iodixanol, the solution is similarly layered to a concentration of two or more layers, and the virus is recovered from the interface where the parvovirus is in equilibrium.

[0073] A parvovirus subjected to density gradient ultracentrifugation using an organic density gradient solution according to the method of the present embodiment can be recovered in a monodispersed state even if it is in an aggregated state before the density gradient ultracentrifugation.

[0074] The maparvovirus-containing solution obtained by density gradient ultracentrifugation using an organic density gradient solution can be further subjected to solvent exchange, for example, dialysis using a semipermeable membrane, solvent exchange using an ultrafiltration membrane, a combination of ultrafiltration membrane and centrifugation, or solvent exchange using a desalting column.

[0075] In order to confirm whether or not the parvovirus is aggregated in a parvovirus-containing solution obtained by density gradient ultracentrifugation using an organic density gradient solution, the solution may be filtered through a filter having a pore size of 80 nm to 30 nm, and the amount of virus before and after filtration may be measured in terms of the infectivity titer or the like.

[0076] The pore size of the filtration membrane is preferably 75 nm to 35 nm, more preferably 40 nm to 30 nm, and most preferably 35 nm.

[0077] The recovery rate of parvovirus obtained from a parvovirus-containing solution by density gradient ultracentrifugation can be determined as the recovery rate of absolute infectivity titer obtained by the formula infectivity titer x volume. As used herein, "absolute infectivity titer" means a value obtained by multiplying the infectivity titer by the volume.

[0078] For example, if the infectivity of a solution containing a mouse retrovirus is 10 9 TCID 50 / mL × 1000mL, the absolute infectivity of the purified raw material is 10 12 TCID 50 In contrast, the mouse minute virus-containing solution obtained by density gradient ultracentrifugation was 10 11 TCID 50 / mL × 10mL, the absolute infectivity of the purified product is also 10 12 TCID 50 Therefore, the recovery rate is 100%.

[0079] The monodispersed parvovirus-containing solution obtained by the method of the present embodiment has a recovery rate of 30% or more, more preferably 50% or more, before and after density gradient ultracentrifugation using an organic density gradient solution. The reason for such a high recovery rate is that the density gradient ultracentrifugation step using an organic density gradient solution provided by the present embodiment is not complicated and takes a relatively short time, thereby making it possible to avoid inactivation of the virus over time.

[0080] In the present embodiment, by evaluating the virus clearance performance of the virus removal membrane using a monodispersed parvovirus-containing liquid, the virus clearance performance, which has conventionally been overestimated, can be evaluated more accurately. The monodispersed parvovirus to be used may be one produced by the method described in the present specification, and there is no particular limitation on the monodispersed parvovirus produced by any other method as long as it is a monodispersed virus.

[0081] In the present embodiment, the virus removal membrane is not particularly limited as long as it is a membrane capable of removing viruses, but is preferably a virus removal membrane for parvovirus. An example of a virus removal membrane for parvovirus is a filtration membrane having an LRV of 4 or more against MVM. A filtration membrane having an LRV of 4 or more against MVM is a filtration membrane having an LRV of 4 or more against MVM, in which 50 L / m of a solution containing MVM is applied to the filtration membrane to be used. 2 The membrane has an LRV of 4 or more when loaded with MVM. The solution containing MVM is a 1 mg / mL human immunoglobulin solution (0.1 M NaCl, pH 4.5) with an MVM concentration of 10 6 TCID 50 / mL is used. The virus removal membrane for parvovirus is not particularly limited as long as its average pore size is approximately equal to or smaller than the size of the parvovirus, but examples thereof include a range of 5 to 24 nm, a range of 14 to 22 nm is preferred, and a range of 18 to 20 nm is more preferred. Examples of virus removal membranes for removing parvovirus include Planova 20N, Planova BioEX, Pegasus SV4, Virosart CPV, and Viresolve Pro, and particularly examples thereof include Planova 20N, Planova 15N, Planova BioEX, Ultipore VF-DV20, Pegasus Prime, Pegasus SV4, or Viresolve Pro, Virosart CPV, and Virosart HF.

[0082] In this embodiment, the virus clearance performance of the virus removal membrane can be evaluated as follows. It is preferable to carry out the evaluation under conditions that are scaled down from the actual production process of a biological product or the like.

[0083] First, a monodispersed parvovirus-containing solution is added to a solution containing a protein such as an intermediate product of a biological product. Examples of proteins include, but are not limited to, globulins from plasma fraction preparations, albumin, blood coagulation factor VII (F-VII), blood coagulation factor VIII (F-VIII), recombinant proteins, monoclonal antibodies, thrombomodulin preparations, tumor necrosis factors, proteinaceous vaccines, culture media, culture media additives, and protease.

[0084] After the addition of the liquid containing the parvovirus, it can be confirmed that the parvovirus in the protein-containing solution is in a monodispersed state by filtering the solution using a prefilter. The pore size of the prefilter is, for example, 75 nm to 25 nm, more preferably 40 to 30 nm, and most preferably 35 nm. The logarithmic removal rate (LRV) of the parvovirus by the prefilter is measured. It is confirmed that the LRV is less than 1.0.

[0085] Next, two samples of the protein-containing solution after prefiltration that will be applied to the virus removal membrane are taken: one is promptly frozen and stored, and the other is left under the same environment as the filtration conditions until filtration is complete, to serve as a control.

[0086] Next, the monodispersed parvovirus is subjected to a virus removal membrane. The method of subjecting the monodispersed parvovirus to a virus removal membrane is not particularly limited as long as the parvovirus can be removed, and an example thereof is filtering the monodispersed parvovirus through the virus removal membrane. Examples of the liquid feeding method during filtration include pressure filtration and low-speed pump filtration. The transmembrane pressure difference during filtration can be within the pressure resistance of the filter used. For example, in the case of Planova 20N, filtration can be performed at 70 to 100 kPa, and in the case of Planova BioEX, filtration can be performed at 196 to 343 kPa. After a predetermined amount of filtration is completed, a part of the filtrate is collected.

[0087] If the virus removal rate is not measured immediately, the sampled filtrate and the control sample taken before filtration can be frozen and stored, and then thawed together with the sampled pre-filtration solution at a later date to measure the virus titer. If the virus removal rate is measured immediately, the sampled pre-filtration solution that was frozen first is thawed, and the virus titer is measured together with the post-filtration solution and the control.

[0088] The virus titer is measured by a known method such as the plaque method or the TCID50 method. The virus titer of the pre-filtration solution is compared with that of the control product to confirm that there is no decrease in titer during filtration. The pass / fail judgment can be determined in advance according to the risk of measurement variability, etc. The logarithmic removal rate is calculated from the difference in the logarithmic virus titer of the solution before and after filtration. For example, if the virus titer of the solution before filtration is 10 6.0 TCID 50 / mL, the virus titer of the filtered solution is 10 2.0 TCID 50 / mL, the log reduction rate is 4.0. EXAMPLES

[0089] The present invention will be described in detail below with reference to examples, but the present invention is not limited to the following examples. The test methods shown in the examples are as follows.

[0090] Example 1 Transformed human fibroblasts (hereinafter referred to as "host cells") were used as host cells for the minute virus of mice, and the cells were incubated at 37°C in a 5% CO2 environment in DMEM supplemented with 10% fetal bovine serum (hereinafter referred to as "10% serum medium") for 75 cm 2 The host cells were subcultured in a 15 mL tissue culture flask (hereafter referred to as "flask"). The host cells were peeled off from the flask and transferred to a new flask at 1.5 × 10 6 The cells were seeded in DMEM medium containing 2.5% FBS (hereinafter referred to as "2.5% serum medium") at a density of cells / 15 ml / flask and infected with minute virus of mouse at an MOI of 0.01. After 4 days, the medium was replaced with medium not containing serum (hereinafter referred to as "serum-free medium") and cultured for another 3 days.

[0091] The culture supernatant containing minute virus of mice was collected and centrifuged at 3,000 rpm for 20 minutes to remove precipitated cell debris, and the supernatant was simply purified by filtration through a 0.45 μm filter (Nalgene) to obtain the culture supernatant.

[0092] The simply purified culture supernatant was ultracentrifuged at 29,400 rpm for 2 hours using a Type 45 Ti rotor (Beckman Coulter Optima L-90K) to precipitate minute virus of mice. The supernatant was removed, and the precipitated minute virus of mice pellet was resuspended in 6 mL of TNE buffer (50 mM Tris-HCl pH 7.4 / 100 mM NaCl / 1 mM EDTA) to obtain a concentrated TNE buffer containing minute virus of mice (hereinafter referred to as "concentrated MVM culture solution").

[0093] The infectivity titer of the concentrated MVM culture medium was measured. The infectivity titer was measured by incubating 2 × 10 host cells in a 96-well plate. 4 After dispensing cells / well, 10-fold serially diluted samples were added to 4 wells each, and the TCID 50 / mL was calculated.

[0094] Next, a sucrose density gradient solution (sucrose / TNE buffer) was prepared under the overlay condition (1) or (2) in Table 1, and the above-mentioned concentrated MVM culture solution was overlaid on the top surface of each.

[0095] [Table 1] (The order of the elements in the above layering conditions is from the bottom to the top of the centrifuge tube.)

[0096] Density gradient ultracentrifugation was performed at 24,000 rpm (103,900 g) for 19 hours using a swing rotor SW-28 (Beckman Coulter) in an ultracentrifuge (Optima L-90K, Beckman Coulter). After ultracentrifugation, 3 mL fractions were collected from the top using a micropipette (total of 12 fractions), and the virus infectivity was measured by the method described above.

[0097] Two consecutive fractions (3 mL per fraction x 2 = 6 mL) that reached the peak of the minute virus of mice infectivity were pooled as a minute virus of mice solution. This minute virus of mice solution was added to a 1% human globulin aqueous solution (0.1 M NaCl) and filtered through a Planova 35N filter (manufactured by Asahi Kasei Medical Co., Ltd.), which is a separation membrane with a pore size of 35 nm. The filtration conditions were 49 kPa, 10 L / m 2 It was decided.

[0098] The recovery rate of minute virus of mice by sucrose density gradient ultracentrifugation was 100% or more under both conditions (1) and (2) (Table 2). The infectivity titer of minute virus of mice was measured before and after filtration, and the logarithmic removal rate (LRV) was calculated according to the following formula (Table 3). LRV = {pre-filtration mouse minute virus infectivity titer (log 10 [TCID 50 / mL])}-{Post-filtration mouse minute virus infectivity titer (log 10 [TCID 50 / mL) After sucrose density gradient ultracentrifugation, the log removal rate of minute virus of mice was less than 1 and the virus was in a monodisperse state (Table 3).

[0099] [Table 2] Conditions: Corresponding to the condition numbers in Table 1. MVM: Minute virus of mice Recovery rate = 100 × (infectivity titer of MVM after density gradient ultracentrifugation × volume) / (infectivity titer of MVM culture fluid before density gradient ultracentrifugation × volume)

[0100] [Table 3]

[0101] Example 2 A concentrated MVM culture medium was obtained in the same manner as in Example 1 above. Next, a sucrose density gradient solution (sucrose / TNE buffer) was prepared according to the layering conditions in Table 3, and after leaving it to stand at 4°C for 16 hours, the above-mentioned concentrated MVM culture solution was layered on the top surface of each.

[0102] [Table 4] (The order of the elements in the above layering conditions is from the bottom to the top of the centrifuge tube.) Density gradient ultracentrifugation was performed at 24,000 rpm (103,900 g) for 19 hours using a swing rotor SW-28 (Beckman Coulter) in an ultracentrifuge (Optima L-90K, Beckman Coulter). After ultracentrifugation, 1 mL fractions were collected from the top using a micropipette (total of 12 fractions), and the virus infectivity was measured by the method described above. Three consecutive fractions (3 mL per fraction x 3 = 9 mL) which reached the peak of the minute virus of mice infectivity titer were pooled as a minute virus of mice-containing solution.

[0103] The recovery rate of minute virus of mice by sucrose density gradient ultracentrifugation was 60% (Table 5).

[0104] [Table 5] Conditions: Corresponding to the condition numbers in Table 4.

[0105] This liquid containing minute virus of mice was filtered through a Planova 35N filter (manufactured by Asahi Kasei Medical Co., Ltd.) in the same manner as in Example 1, and the logarithmic removal rate (LRV) was calculated (Table 6).

[0106] [Table 6]

[0107] After sucrose density gradient ultracentrifugation, the minute virus of mice had a log reduction rate of less than 1 and was monodispersed (Table 6).

[0108] Comparative Example 1 Three batches of culture supernatant containing minute virus of mice were collected from the culture supernatant in the same manner as in Example 1. Each batch was centrifuged at 3,000 rpm for 20 minutes to remove precipitated cell debris, and the supernatant was filtered through a 0.45 μm filter (manufactured by Nalgene).

[0109] These were filtered through a Planova 35N filter in the same manner as in Example 1, without going through a density gradient ultracentrifugation step using an organic density gradient solution, and the logarithmic removal ratio (LRV) was calculated.

[0110] Comparative Example 2 A concentrated MVM culture solution was obtained in the same manner as in Example 1. This was filtered through a Planova 35N filter in the same manner as in Example 1, without going through a density gradient ultracentrifugation step using an organic density gradient solution, and the logarithmic removal rate (LRV) was calculated.

[0111] Comparative Example 3 A concentrated MVM culture solution was obtained in the same manner as in Example 1. However, PBS(-) buffer was used to resuspend the virus pellet obtained by ultracentrifugation instead of TNE buffer. This was filtered through a Planova 35N filter in the same manner as in Example 1 without going through a density gradient ultracentrifugation step using an organic density gradient solution, and the logarithmic removal rate (LRV) was calculated.

[0112] The results are shown in Table 7.

[0113] [Table 7]

[0114] The minute viruses of mice that were not subjected to density gradient ultracentrifugation using an organic density gradient solution had a logarithmic removal rate of 1 or more on the 35 nm filter and were in an aggregated state in all of Comparative Examples 1, 3, and 3. This means that the minute viruses of mice that would normally pass through Planova 35N were captured by Planova 35N, suggesting that when the performance of the virus removal membrane is evaluated using the viruses of Comparative Examples 1 to 3, the virus clearance performance of the virus removal membrane is overestimated.

Claims

1. 1) subjecting a parvovirus-containing solution to density gradient ultracentrifugation using an organic density gradient solution; 2) recovering a fraction containing the parvovirus, the parvovirus is minute virus of mice, the density gradient in the density gradient ultracentrifugation is a step gradient density gradient, The density gradient solution is a stepwise density gradient solution including at least a sucrose solution layer of 40% or less and a sucrose solution layer of 50% or more, The method for producing a monodispersed parvovirus, wherein the product (h×g) of relative centrifugal force (g)×centrifugation time (h) in the density gradient ultracentrifugation is 1,500,000 to 7,000,000 (h×g).

2. The method according to claim 1, wherein the parvovirus-containing liquid is a culture supernatant of cells infected with a parvovirus and / or a lysate of said cells.

3. The method according to claim 1 or 2, wherein the logarithmic removal value (LRV) of the monodispersed parvovirus when filtered through a membrane having a pore size of 35 nm is less than 1.

0.

4. The method according to any one of claims 1 to 3, wherein the density gradient is a step density gradient comprising a 40% sucrose solution layer and a 60% sucrose solution layer.

5. The method according to any one of claims 1 to 3, wherein the density gradient solution is a step density gradient solution comprising a 15% sucrose solution layer, a 30% sucrose solution layer, a 45% sucrose solution layer, and a 60% sucrose solution layer.

6. The method according to any one of claims 1 to 5, further comprising a step of exchanging the solvent of the parvovirus-containing fraction.

7. The method according to any one of claims 1 to 6, wherein the recovery rate of the parvovirus is 50% or more.

8. The method according to any one of claims 1 to 7, wherein the density gradient solution is a step density gradient solution comprising at least a sucrose solution layer of 60% or more and a sucrose solution layer of more than 30% and less than 60%.

9. A step of subjecting a parvovirus-containing liquid to density gradient ultracentrifugation using an organic density gradient liquid to obtain a monodispersed parvovirus; adding the monodispersed parvovirus to a protein-containing solution; filtering the protein-containing liquid through a virus removal membrane; Quantifying the amount of virus in the protein-containing liquid before and after filtration; Including, Parvovirus is a minute virus of mice, the density gradient in the density gradient ultracentrifugation is a step gradient density gradient, The density gradient solution is a stepwise density gradient solution including at least a sucrose solution layer of 40% or less and a sucrose solution layer of 50% or more, The method for evaluating the virus clearance performance of a virus removal membrane, wherein the product (h×g) of the relative centrifugal force (g)×centrifugation time (h) of the density gradient ultracentrifugation is 1,500,000 to 7,000,000 (h×g).

10. 10. The method of claim 9, wherein the density gradient is a step density gradient comprising at least a sucrose solution layer of 60% or more and a sucrose solution layer of more than 30% and less than 60%.

11. The method described in claim 9 or 10, wherein the amount of virus is a virus titer measured by the plaque method or the TDID50 method.

Citation Information

Patent Citations

  • Method for producing high-titer, high-purity virus stocks and method for using them.

    JP2013523175A

  • Purification of Recombinant Adeno-associated Virus Particles by Multistep Anion Exchange Chromatography

    JP2018518164A

  • Method for mass production and purification of parvovirus

    JP2018523992A

  • Gene Therapy for Age-Related Diseases and Conditions

    JP2019519221A

  • Methods of producing high titer, high purity virus stocks and methods of use thereof

    US20120088228A1